Progyny (PGNY) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
14 Jan, 2026Executive summary
Q3 2024 revenue increased 2% year-over-year to $286.6 million, driven by growth in clients and covered lives, but results missed guidance due to lower ART cycle consumption and atypical member patterns.
Net income for Q3 2024 was $10.4 million ($0.11 per diluted share), down from $15.9 million ($0.16) in Q3 2023, reflecting lower gross margin and higher tax provision.
Gross margin declined to 20.7% from 22.3% year-over-year, mainly due to higher personnel-related costs and lower cycles per utilizer.
Adjusted EBITDA for Q3 2024 was $46.5 million, a 7% decrease from Q3 2023, with a margin of 16.2%.
Over 80 new clients and 1.1 million new covered lives were added, with strong adoption of new maternity, postpartum, and menopause services for 2025.
Financial highlights
Q3 2024 revenue: $286.6 million (+2% YoY); nine-month revenue: $868.8 million (+6% YoY).
Q3 2024 gross profit: $59.2 million (down 5% YoY); gross margin: 20.7% (down 160 bps YoY).
Q3 2024 Adjusted EBITDA: $46.5 million (down from $50.0 million YoY); nine-month Adjusted EBITDA: $151.2 million (up from $143.8 million YoY).
Q3 2024 net income: $10.4 million (down from $15.9 million YoY); nine-month net income: $43.8 million (down from $48.6 million YoY).
Operating cash flow for Q3 was $44.5 million, and $127 million year-to-date, with 84% conversion of Adjusted EBITDA.
Outlook and guidance
Q4 2024 revenue expected between $266.2 million and $281.2 million; full-year revenue guidance is $1.135 billion to $1.150 billion.
Q4 Adjusted EBITDA projected at $37.8 million–$42.8 million; net income $6.1 million–$9.5 million.
Full-year Adjusted EBITDA expected at $189 million–$194 million; net income $49.9 million–$53.3 million.
Guidance assumes continued variability in ART cycles per utilizer and utilization rates, with the loss of a major client in 2025 expected to impact future revenue.
Over 530 clients and 6.7 million covered lives expected in 2025 after new client launches.
Latest events from Progyny
- Strong utilization and new product launches drive growth amid stable competition and tech investment.PGNY
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Stable growth, high retention, and new market expansion drive a positive long-term outlook.PGNY
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Record 2025 revenue and margin gains, with 2026 guidance projecting further growth.PGNY
Q4 202526 Feb 2026 - Q2 revenue up 9%, guidance cut 5%, with record margins and $100M added to share buybacks.PGNY
Q2 20242 Feb 2026 - Targets $2.4B+ revenue and 20% CAGR by 2028, fueled by new women's health products.PGNY
Investor Day 20242 Feb 2026 - Utilization rebounded after a Q1 dip, with strong membership growth and a favorable outlook.PGNY
Jefferies 2024 Global Healthcare Conference31 Jan 2026 - Progyny Select expands reach to small employers, fueling growth and diversification in 2026.PGNY
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - High retention, strong sales, and new product growth support a positive long-term outlook.PGNY
Jefferies London Healthcare Conference 202413 Jan 2026 - Growth, retention, and new women's health offerings drive market leadership and value.PGNY
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026